Clinical Trial

Study of Live Attenuated Varicella Vaccine Co-administered with MMR Vaccine or DTaP Vaccine

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated March 24, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a phase Ⅳ clinical trial of live attenuated varicella vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.The primary objective of this study is to evaluate the immunogenicity of live attenuated varicella vaccine co-administered with MMR vaccine or DTaP vaccine. The secondary objective is to evaluate the safety of the vaccines when administered simultaneously.
Trial Details
NCT Number NCT06891872
Lead Sponsor Sinovac (Dalian) Vaccine Technology Co., Ltd.
Conditions Varicella (chickenpox), MMR Vaccine, DTaP Vaccine
Enrollment 720 participants
Start Date 2025-05
Primary Completion 2025-12 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-03-24